Clinical Trials for Kidney Cancer

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced selected solid tumors who have exhausted or are ineligible for standard treatment receive oral TT-10 (PORT-6), an adenosine A2A receptor antagonist, oral TT-4 (PORT-7), an adenosine A2B receptor antagonist, or both. Eligible tumor types vary by cohort and include RCC, CRPC, NSCLC, head and neck, colorectal, endometrial, and ovarian cancers.

ClinicalTrials.gov ID: NCT04969315

A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients have measurable locally advanced or metastatic solid tumors, ECOG performance status ≤2, and at least one prior systemic therapy; expansion cohorts focus on previously treated head and neck squamous cell carcinoma, non-small-cell lung cancer, clear-cell renal cell carcinoma, and PD-1/PD-L1-refractory MSI-high tumors. Treatment is oral ABBV-CLS-484, an investigational PTPN2/PTPN1 inhibitor, alone or with a PD-1 inhibitor or VEGFR tyrosine kinase inhibitor.

ClinicalTrials.gov ID: NCT04777994

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with incurable locally advanced, recurrent, or metastatic solid tumors and ECOG performance status 0–1 receive IV RO7502175 (enzelkitug) alone or with atezolizumab or pembrolizumab. RO7502175 is an investigational afucosylated anti-CCR8 antibody designed to deplete tumor-associated regulatory T cells.

ClinicalTrials.gov ID: NCT05581004

Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients aged 16–80 with previously treated, advanced CD70-positive clear cell renal cell carcinoma or mesothelioma, or recurrent/refractory CD70-positive osteosarcoma, receive fludarabine/cyclophosphamide lymphodepletion followed by allogeneic cord blood–derived CAR.70/IL15 NK cells. The investigational NK cells use a CD27-based receptor to recognize CD70 and express IL-15 to support their activity and persistence.

ClinicalTrials.gov ID: NCT05703854

An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced solid tumors lacking standard treatment options may receive intravenous ADU-1805 alone or with pembrolizumab; combination expansion cohorts enroll selected patients with microsatellite-stable colorectal or endometrial cancer, renal cell carcinoma, or non-small cell lung cancer. ADU-1805 is an investigational anti-SIRPα antibody designed to block the SIRPα–CD47 signal and promote macrophage engulfment of tumor cells.

ClinicalTrials.gov ID: NCT05856981

A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults on chronic hemodialysis with advanced clear-cell or papillary renal cell carcinoma who lack or decline appropriate conventional therapy receive intravenous orellanine (ONC175). This investigational mushroom-derived toxin injures renal proximal-tubule cells and may act through oxidative stress and disruption of cellular metabolism and protein synthesis; its precise molecular target is unknown.

ClinicalTrials.gov ID: NCT05287945